ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2011
Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 186 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial
A Randomized Control Trial to Compare Doxycycline to Isotretinoin for the Treatment of Acneiform Eruptions in Cancer Patients on Tyrosine Kinase Inhibitors
Who cites it
186 citing papers in PubMed, 6 syntheses or guidelines pooled it, 428 citations in OpenAlex.
- Rash associated with epidermal growth factor receptor inhibitors: a systematic review and meta-analysis of 194 randomized controlled trials.Frontiers in immunology · 2026Pooled it
- Best evidence summary for the management of epidermal growth factor receptor inhibitor-induced skin toxicity symptoms in cancer patients.Frontiers in medicine · 2025Pooled it
- A technical appraisal of guidelines for the management of skin rash in patients on chemotherapy and targeted therapy.BMC health services research · 2019Pooled it
- Alopecia in patients treated with molecularly targeted anticancer therapies.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Pooled it
- Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.PharmacoEconomics · 2014Pooled it
- The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.Targeted oncology · 2013Pooled it
- Trial
- Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer.International journal of colorectal disease · 2021Trial
- Trial
- Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance).Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Trial
- Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-IIIJCO precision oncology · 2021Trial
- Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial.BMJ open · 2020Trial
- A Randomized Controlled Trial of Epidermal Growth Factor Ointment for Treating Epidermal Growth Factor Receptor Inhibitor-Induced Skin Toxicities.The oncologist · 2020Trial
- Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).The oncologist · 2019Trial
- Trial
- Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Trial
- Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.Clinical breast cancer · 2016Trial
- Xerosis and pruritus as major EGFRI-associated adverse events.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
126 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEpidermal growth factor receptor inhibitors (EGFRI) produce various dermatologic side effects in the majority of patients, and guidelines are crucial for the prevention and treatment of these untoward events. The purpose of this panel was to develop evidence-based recommendations for EGFRI-associated dermatologic toxicities.
methodsA multinational, interdisciplinary panel of experts in supportive care in cancer reviewed pertinent studies using established criteria in order to develop first-generation recommendations for EGFRI-associated dermatologic toxicities.
resultsProphylactic and reactive recommendations for papulopustular (acneiform) rash, hair changes, radiation dermatitis, pruritus, mucositis, xerosis/fissures, and paronychia are presented, as well as general dermatologic recommendations when possible.
conclusionPrevention and management of EGFRI-related dermatologic toxicities is critical to maintain patients' health-related quality of life and dose intensity of antineoplastic regimens. More rigorous investigation of these toxicities is warranted to improve preventive and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.